Total Funding
71
63
Total FundingPost-IPO Equity raised
Growth Score
20 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3723
Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Acquired by 
Avenzo Therapeutics
- Stephen Uden: Co-Founder
Martin Mackay: Co-FounderPast Role: Alexion Pharmaceuticals, Executive Vice President, Global Head of Research & Development.
About the Company
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas
of hematology, immuno-inflammation,,maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.
